Nurse Practitioner in Hickory Hills, IL Accepting Medicare
3 Nurse Practitioner nurses found. Showing 1 - 3
 Paulina Anna Sarat, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 9109 Kopping Ln, Hickory Hills, IL 60457 Phone: 708-351-4304 |
Revi Chari Manipol Brinkman, Nurse Practitioner - Gerontology Medicare: Not Enrolled in Medicare Practice Location: 9437 S 84th Ave, Hickory Hills, IL 60457 Phone: 714-343-7712 |
Avani Patel, NP Nurse Practitioner - Psych/Mental Health Medicare: Medicare Enrolled Practice Location: 8800 Active Ln, Hickory Hills, IL 60457 Phone: 708-296-6655 |
News Archive
Some stroke patients may benefit from cerebral angioplasty and stent placement
Some stroke patients may benefit from cerebral angioplasty and stent placement, according to a new study published online in the journal Radiology.
Chao BRAIN Center receives $5M gift for study of progressive neurodegenerative diseases
Dr. Stephen Wong has received a $5 million gift from the Ting Tsung and Wei Fong Chao Foundation to study progressive neurodegenerative diseases including Alzheimer's Disease. The gift will support The Ting Tsung and Wei Fong Chao Center for Bioinformatics Research and Imaging for Neurosciences (BRAIN) at The Methodist Hospital Research Institute.
Having high blood pressure in midlife can affect cognition many years later
Having high blood pressure in your 50's may impact your ability to keep track or plan ahead in your 80's. This study reports a connection between high blood pressure at a younger age can affect cognition many years later. It currently appears in the Journal of Alzheimer's Disease.
Accumulation of genetic changes is not solely determined by natural selection
New data suggest that the accumulation of genetic changes is not solely determined by natural selection. A study by University of Chicago researchers contradicts conventional theory by showing that the percentage of mutations accepted in evolution is also strongly swayed by the speed at which new mutations arrive at a gene: the faster the speed of new mutations, the greater the percentage of those mutations accepted.
First patient included in the phase II study of Amphinex® in head and neck cancer patients
PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the first patient has been included in the phase II study of Amphinex in combination with the cytotoxic agent bleomycin in head and neck cancer patients, called the ENHANCE study. The first patient was included at the National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Germany. NCT is a joint project of the German Cancer Research Center (DKFZ), Heidelberg University Hospital, Thoraxklinik Heidelberg and Deutsche Krebshilfe (German Cancer Aid).
› Verified 5 days ago